YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Clinical trial NCT07461454 · RECRUITING

Trial details

NCT number: NCT07461454
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Breast Cancer

Start date: 2026-03-17
Primary completion: 2027-12-31
Enrollment: 376

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.